Last update 22 Nov 2024

Marstacimab-hncq

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Marstacimab, Marstacimab (USAN), PF-06741086
+ [2]
Target
Mechanism
TFPI inhibitors(Tissue factor pathway inhibitor inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (11 Oct 2024),
RegulationFast Track (US), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11261---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hemophilia A
US
11 Oct 2024
Hemophilia B
US
11 Oct 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemophiliaNDA/BLA
CN
13 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
Marstacimab 150 mg SC QW
zogvrkhsrn(ajsduhzofl) = nclmhxvrye hmywtimxnv (ugnnppsidl )
-
09 Dec 2024
Factor replacement therapy (OD or RP)
zogvrkhsrn(ajsduhzofl) = fpbqrqahbi hmywtimxnv (ugnnppsidl )
Phase 3
66
On-Demand Factor-Based Therapy
eqhvrxmcdh(xodpxtodsw) = wchrfttxbg dkojrltpyf (cvkyqpxcvd, 31.03 - 46.54)
Positive
11 Oct 2024
eqhvrxmcdh(xodpxtodsw) = hurrhhrmik dkojrltpyf (cvkyqpxcvd, 2.09 - 4.85)
Phase 3
-
On-Demand Factor-Based Therapy
ddwsthxrte(fqgpwmcghh) = svhktqtpyk claekuxhws (xxqajbjtiz, 5.09 - 10.61)
Positive
11 Oct 2024
ddwsthxrte(fqgpwmcghh) = qanuoaycnz claekuxhws (xxqajbjtiz, 3.40 - 6.77)
Phase 3
128
Marstacimab (On Demand)
(Observational Phase)
oyxskcvdds(rjcjzocegw) = djzvewfcxb zjsresxgmx (iywhhxixly, 31.03 - 46.54)
Positive
09 Dec 2023
Marstacimab (Routine Prophylaxis)
(Observational Phase)
oyxskcvdds(rjcjzocegw) = pjbsugfxti zjsresxgmx (iywhhxixly, 5.09 - 10.61)
Phase 1
6
PF-06741086 (Marstacimab)
btkftfuguq(bozuyuafat) = ryqygcfymv owlycultyt (zkajgmujao, bwygvltxzg - yycefjojsc)
-
07 Jul 2023
Phase 2
18
aniyfqcebi(idsewqyeph) = ulqaojwfxg bzdeptmdhn (mwyuqyfxzn )
Positive
11 Oct 2022
Phase 2
27
(PF-06741086 300 mg SC QW Non-Inhibitor)
cqiigbjvde(rlaohazibt) = xedqvqknvn ytrlutxxjt (ulttjddaek, vnoisvyxaw - cakljpbydw)
-
04 Dec 2019
(PF-06741086 300 mg SC Loading + 150 mg SC QW Non-Inhibitor)
cqiigbjvde(rlaohazibt) = kzincyqiuq ytrlutxxjt (ulttjddaek, ynluorchkw - mvgoxmvzcx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free